A detailed history of Affinity Capital Advisors, LLC transactions in Renovo Rx, Inc. stock. As of the latest transaction made, Affinity Capital Advisors, LLC holds 13,279 shares of RNXT stock, worth $17,262. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,279
Previous 13,279 -0.0%
Holding current value
$17,262
Previous $15,000 6.67%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

Apr 11, 2023

SELL
$2.51 - $5.25 $4,969 - $10,395
-1,980 Reduced 12.98%
13,279 $46,000
Q4 2022

Jan 18, 2023

BUY
$1.65 - $2.35 $6,614 - $9,421
4,009 Added 35.64%
15,259 $0
Q3 2022

Oct 12, 2022

BUY
$1.84 - $2.79 $20,700 - $31,387
11,250 New
11,250 $23,000

Others Institutions Holding RNXT

About RenovoRx, Inc.


  • Ticker RNXT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 9,066,860
  • Market Cap $11.8M
  • Description
  • RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, In...
More about RNXT
Track This Portfolio

Track Affinity Capital Advisors, LLC Portfolio

Follow Affinity Capital Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Affinity Capital Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Affinity Capital Advisors, LLC with notifications on news.